Shares of Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) have been given an average recommendation of “Hold” by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $8.50.
ANIX has been the subject of several research reports. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. HC Wainwright reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Finally, Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th.
View Our Latest Stock Analysis on ANIX
Anixa Biosciences Stock Down 0.7%
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last announced its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. As a group, equities analysts forecast that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, CEO Amit Kumar acquired 21,000 shares of Anixa Biosciences stock in a transaction on Friday, June 12th. The stock was acquired at an average cost of $2.50 per share, with a total value of $52,500.00. Following the completion of the acquisition, the chief executive officer owned 630,812 shares in the company, valued at approximately $1,577,030. This trade represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 26.40% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ANIX. 683 Capital Management LLC bought a new position in shares of Anixa Biosciences during the 4th quarter worth $355,000. ExodusPoint Capital Management LP bought a new stake in Anixa Biosciences in the 4th quarter valued at about $293,000. Susquehanna International Group LLP raised its stake in Anixa Biosciences by 378.4% in the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after acquiring an additional 63,584 shares during the period. Virtu Financial LLC purchased a new stake in Anixa Biosciences during the fourth quarter valued at about $161,000. Finally, State Street Corp boosted its position in Anixa Biosciences by 32.0% during the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after purchasing an additional 38,540 shares during the period. Hedge funds and other institutional investors own 29.13% of the company’s stock.
Anixa Biosciences Company Profile
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Featured Articles
- Five stocks we like better than Anixa Biosciences
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
